Literature DB >> 16186587

Rebalancing ratios and improving impressions: later thoughts from the prostate cancer prevention trial investigators.

James A Talcott.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16186587     DOI： 10.1200/JCO.2005.07.909

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  2 in total

1.  [The Prostate Cancer Prevention Trial (PCPT). Relevance for clinical practice].

Authors:  B J Schmitz-Dräger; C Fischer; E Bismarck; H J Dörsam; G Lümmen
Journal:  Urologe A       Date:  2007-10       Impact factor: 0.639

Review 2.  Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline.

Authors:  Barnett S Kramer; Karen L Hagerty; Stewart Justman; Mark R Somerfield; Peter C Albertsen; William J Blot; H Ballentine Carter; Joseph P Costantino; Jonathan I Epstein; Paul A Godley; Russell P Harris; Timothy J Wilt; Janet Wittes; Robin Zon; Paul Schellhammer
Journal:  J Clin Oncol       Date:  2009-02-24       Impact factor: 44.544
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.